The separate-basis 2025 financial statements were approved at the annual general meeting on March 31, 2026.
According to the same filing, total assets were KRW 10,539 million, revenue was KRW 153 million, total liabilities were KRW 11,647 million, operating loss was KRW 4,926 million, and net loss was KRW 3,025 million, with total equity at KRW -1,108 million. Loss per share was recorded at KRW 646.
On a 2024 settlement basis, revenue was reported at about KRW 500 million and operating loss at about KRW 5.8 billion, so 2025 revenue fell sharply from that level. Shares outstanding at year-end 2024 comprised 3,725,041 common shares and 1,392,533 preferred shares.
In October 2024, SD Biosensor applied for a payment order over KRW 19.62 billion tied to the third series of bonds with warrants, which moved the dispute into court proceedings.
Reports later said SD Biosensor would convert its 1,022,495 redeemable convertible preferred shares into common stock in full and the company would repay 75% of the bond principal and interest, settling the dispute.
On April 16, 2026, the company announced a US patent for core technology of its next-generation implantable CGM, and on September 23, 2026, it self-disclosed a patent for a continuous analyte measuring device.
In August 2026, a rights offering decision and a convertible bond issuance decision went through corrective filings, followed by an advance notice of an unfaithful-disclosure designation on September 2 and the designation itself on September 14, based on a reversal of disclosure. As of September 30, 2026, the share price was KRW 6,170, with a 52-week range of KRW 4,870 to KRW 11,980.